Repurposing Cimetidine as a Therapeutic Candidate for Irritable Bowel Syndrome in a Rat Model
Fundamental & Clinical Pharmacology · 2026-05 · 40 (3)
DOI: 10.1111/fcp.70091 ↗Kurz gefasst
Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, online erschienen am 04.05.2026. Verfasst von Tsukasa Nozu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Regional Medicine and Education, Asahikawa Medical University, Asahikawa, Hokkaido, Japan. Hauptthemen laut MEDLINE: Cimetidine, Irritable Bowel Syndrome, Histamine H2 Antagonists. Die Arbeit nennt 64 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science KAKENHI, Scientific Research on Innovative Areas.
Abstract (Originalsprache)
Background
Visceral hypersensitivity and impaired intestinal barrier function are hallmark features of irritable bowel syndrome (IBS), linked to activation of corticotropin‐releasing factor (CRF), Toll‐like receptor 4 (TLR4), and proinflammatory cytokine pathways. Cimetidine, a classical H 2 blocker, has been shown to inhibit Na + /H + exchangers (NHEs), thereby potentially suppressing proinflammatory cytokine release.
Objectives
This study examined whether cimetidine alleviates visceral hypersensitivity and colonic hyperpermeability in rat models of IBS.
Methods
Visceral pain threshold in response to colonic balloon distention was assessed by electromyographic detection of abdominal muscle contractions during colonic balloon distention, and colonic permeability was measured using Evans blue uptake in LPS‐ and CRF‐induced IBS models in male Sprague–Dawley rats.
Results
Intragastric cimetidine (20–100 mg/kg daily for 3 days) prevented LPS‐induced visceral hypersensitivity and colonic hyperpermeability dose‐dependently and also attenuated CRF‐induced changes. In contrast, famotidine, another H 2 blocker, did not replicate these effects. Amiloride, an NHE inhibitor, mimicked cimetidine's effects, both of which were abolished by intracisternal SB‐334867, an orexin 1 receptor antagonist. Furthermore, atropine, sulpiride, and N G ‐nitro‐L‐arginine methyl ester, a nitric oxide (NO) synthesis inhibitor, but not scopolamine butylbromide, a peripheral muscarinic receptor antagonist, or domperidone, a peripheral dopamine D 2 receptor antagonist, blocked cimetidine's action.
Conclusion
These findings suggest that cimetidine prevents visceral hypersensitivity and colonic hyperpermeability in IBS models through mechanisms involving central orexin signaling possibly triggered by NHE inhibition, NO, and central muscarinic and dopamine D 2 receptor pathways. These findings may provide a basis for future therapeutic approaches targeting IBS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Regional Medicine and Education, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
- Center for Medical Education, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
- Department of General Medicine, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
- Division of Neuroscience, Department of Physiology, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
ORCID-Profile: Tsukasa Nozu, Toshikatsu Okumura
Förderung
- Japan Society for the Promotion of Science KAKENHI
- Scientific Research on Innovative Areas
Zitieren
APA
Nozu, T., Miyagishi, S., Ishioh, M., Takakusaki, K., & Okumura, T. (2026). Repurposing Cimetidine as a Therapeutic Candidate for Irritable Bowel Syndrome in a Rat Model. Fundamental & Clinical Pharmacology, 40(3). https://doi.org/10.1111/fcp.70091
Vancouver
Nozu T, Miyagishi S, Ishioh M, Takakusaki K, Okumura T. Repurposing Cimetidine as a Therapeutic Candidate for Irritable Bowel Syndrome in a Rat Model. Fundamental & Clinical Pharmacology. 2026;40(3). doi:10.1111/fcp.70091
BibTeX
@article{Nozu2026,
author = {Nozu, Tsukasa and Miyagishi, Saori and Ishioh, Masatomo and Takakusaki, Kaoru and Okumura, Toshikatsu},
title = {Repurposing Cimetidine as a Therapeutic Candidate for Irritable Bowel Syndrome in a Rat Model},
journal = {Fundamental & Clinical Pharmacology},
year = {2026},
volume = {40},
number = {3},
doi = {10.1111/fcp.70091}
}
EUVIMED